Frontiers in immunology · 2025
Increased long-term central memory T cells in patients with retreatment pulmonary tuberculosis.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Yao Xin, Cai Haomin, Chen Jianxia, Yu Fangyong, Wu Xiaocui, Shi Yarong, Hu Yang, Xu Yuyan, Xu Qinghua, Liu Zhonghua
Аннотация
BACKGROUND: T cells are crucial in controlling Mycobacterium tuberculosis infection and disease progression. Nevertheless, the specific functions and changes of T lymphocyte subsets in retreatment tuberculosis remain poorly understand. The study aims to identify the changes in T lymphocyte subsets and the immunoprotective effect of TCM in retreatment tuberculosis.
METHOD: We collected venous blood from the participants and assessed using flow cytometry. Univariate analysis and regression model were used to evaluate the changes of T lymphocyte subsets and key subsets in retreatment tuberculosis.
RESULTS: In the study, while the frequencies of CD4 and CD8 T cells were similar between primary and retreatment patients, retreatment patients exhibited a significant increase in TCM (P < 0.05), which may represent a protective factor for retreatment (adjusted OR=0.926, 95%CI: 0.860-0.996, P < 0.05) (adjusted OR=0.951, 95%CI: 0.912-0.992, P<0.05). Furthermore, TCM significantly increased in retreatment patients who achieved cure (P < 0.05), though were similar between the cure and no-cure for primary patients; The potentially protective effect of TCM in patients with repeated infection may possibly contribute by improving the efficacy of retreatment chemotherapy (adjusted OR=0.803, 95%CI: 0.677-0.953, P < 0.05) (adjusted OR=0.890, 95% CI: 0.812-0.976, P<0.05), particularly in those with lung injury (adjusted OR=0.780, 95% CI: 0.635-0.957, P< 0.05) (adjusted OR=0.805, 95% CI: 0.660-0.983, P<0.05).
CONCLUSION: Development of adjunct immunotherapies for increasing TCM responses may improve the efficacy of retreatment tuberculosis with existing and with novel chemotherapies.
METHOD: We collected venous blood from the participants and assessed using flow cytometry. Univariate analysis and regression model were used to evaluate the changes of T lymphocyte subsets and key subsets in retreatment tuberculosis.
RESULTS: In the study, while the frequencies of CD4 and CD8 T cells were similar between primary and retreatment patients, retreatment patients exhibited a significant increase in TCM (P < 0.05), which may represent a protective factor for retreatment (adjusted OR=0.926, 95%CI: 0.860-0.996, P < 0.05) (adjusted OR=0.951, 95%CI: 0.912-0.992, P<0.05). Furthermore, TCM significantly increased in retreatment patients who achieved cure (P < 0.05), though were similar between the cure and no-cure for primary patients; The potentially protective effect of TCM in patients with repeated infection may possibly contribute by improving the efficacy of retreatment chemotherapy (adjusted OR=0.803, 95%CI: 0.677-0.953, P < 0.05) (adjusted OR=0.890, 95% CI: 0.812-0.976, P<0.05), particularly in those with lung injury (adjusted OR=0.780, 95% CI: 0.635-0.957, P< 0.05) (adjusted OR=0.805, 95% CI: 0.660-0.983, P<0.05).
CONCLUSION: Development of adjunct immunotherapies for increasing TCM responses may improve the efficacy of retreatment tuberculosis with existing and with novel chemotherapies.